ClinicalTrials.gg
WithdrawnNCT00858182Updated Jun 26, 2019

Study of Safety and Efficacy on New Peritoneal Dialysis Solutions

A Phase 2 interventional study of PD solution for nocturnal exchanges and PD solution for diurnal exchanges in End-Stage Renal Disease, sponsored by Iperboreal Pharma Srl. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by Iperboreal Pharma Srl · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing xylitol and L-carnitine as osmotic agents to partially replace glucose.

02

Conditions studied

  • End-Stage Renal Disease

Keywords

  • L-Carnitine
  • Xylitol
  • Peritoneal Dialysis
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Iperboreal Pharma Srl is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Diagnosis of ESRD treated for at least three month with CAPD, as stated by the medical staff of the center;
  • CAPD treatment with 2.27% of glucose solution for the nocturnal exchange;
  • Stable clinical condition within four weeks before screening period, certified by medical/surgical history, physical examination and laboratory exploration;
  • level ≥9g/dL;
  • Residual diuresis ≤800mL;
  • Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection;
  • Stable peritoneal permeability, as confirmed by a PET between 0.50 and 0.81 during previous three months and at day 0 of the screening period;
  • Total urea Kt/V >1.5 per week at a control during previous three months and at day 0 of the screening period and/or minimal total of 45 liter/week at a control during previous three months and at day 0 of the screening period; 1- To understand and sign an form.

For patients who will be included in Group B, the following criteria must be fulfilled too:

  • Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month
  • Be treated with 2 or 3 diurnal exchange bag solutions (solution bags with 1.36% or 2.27% glucose) and one nocturnal exchange bag solution (Extraneal)

Exclusion criteria

Exclusion Criteria:

  • History of alcohol or drug abuse in the last six months before selection for the study;
  • Androgen therapy in the last six months before selection;
  • Active infections;
  • History of congestive heart failure stage III and IV ;
  • History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection;
  • cardiac arrhythmia;
  • Clinically relevant abnormalities of functional hepatic tests;
  • Therapy with L-carnitine or its derivatives in the last three months before selection;
  • Pregnancy, lactating women or female subjects of who do not use an effective method of ;
  • Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with assessment of study parameters, especially if the life expectation is less then one year;
  • Participation in another clinical study within the past month;
  • Known or supposed allergic reactions to L-carnitine or xylitol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: PD solution for nocturnal exchanges

  • Experimental
    Group B

    Drug: PD solution for diurnal exchanges

Interventions

  • DrugPD solution for nocturnal exchanges

    Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.

  • DrugPD solution for diurnal exchanges

    Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.

06

What researchers measure

Primary outcomes

  1. To assess ultrafiltration efficacy of PD solutions containing L-Carnitine and Xylitol

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Oct 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2009
First posted
Mar 9, 2009
Start
May 2009
Primary completionEst.
Oct 2012
CompletionEst.
Jan 2013
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00858182
Lead sponsor
Iperboreal Pharma Srl
Responsible party
Sponsor
First posted
Mar 9, 2009
Start date
May 2009
Primary completion
Oct 2012 (estimated)
Completion
Jan 2013 (estimated)
Last update
Jun 26, 2019

Study contacts

Cristina Capusa, PhD
study director · "Dr Carol Davila" University Hospital of Nephrology, Romania
Gabriel Mircescu, PhD
study chair · "Dr Carol Davila" University Hospital of Nephrology, Romania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion